Project Grant R01DK142423

Award Date 9/20/24
Completion Date 5/31/29
Dollars Obligated $1.3M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Durham, NC 27701, USA
Similar Awards
This $1,331,148 Project Grant was awarded on June 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Yale University. The funding supports a research project investigating the mechanisms by which pancreatic alpha cells adapt to compensate for reduced beta cell mass in type 2 diabetes. Specifically, the project aims to determine how increased glucagon secretion from alpha cells helps...
This Project Grant award of $126,480.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research aimed at understanding the regulation of intra-islet communication and its role in maintaining normal pancreatic islet function. The principal investigator will pursue a novel hypothesis that the signaling protein 14-3-3-ζ is a crucial regulator of α-cell to β-cell crosstalk, with the goal of...
This federal Project Grant award of $293,604 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to understand the role of the hypothalamic adhesion G-protein coupled receptor L 1 (ADGRL1) in counteracting hypoglycemia (dangerously low blood glucose levels). The primary research aims are to: 1) Establish the contribution of ADGRL1 in the ventromedial nucleus of the hypothalamus...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $410,000.00 to The University of Texas Southwestern Medical Center to study the effects of glucagon-like peptide 1 (GLP-1) receptor agonists and brain-derived GLP-1 on the activity of neuropeptide Y/agouti-related peptide (NPY/AGRP) neurons and their impact on metabolism. The research aims to define the...
This Project Grant award of $153,554 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to unveil novel targets for type 1 diabetes (T1D) therapy. The principal investigator at the Beckman Research Institute of the City of Hope will utilize innovative methodologies, including human pancreatic tissue slices, to investigate the functional heterogeneity...
This $705,817 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, CFDA 93.847) supports research at the University of California, Irvine (UCI) to investigate the differential signaling of cyclic adenosine monophosphate (cAMP) within pancreatic beta cells. The research aims to better understand how cAMP signaling from different intracellular locations, such as the cell surface and endosomes, can have varying effects on insulin secretion and gene...
The National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) awarded a $693,075 Project Grant to Yale University to conduct research targeting the pancreatic endocrine-exocrine signaling in cancer development, with a focus on the potential impact of incretin mimetics (such as glucagon-like peptide-1 receptor agonists) on pancreatic ductal adenocarcinoma (PDAC). The research aims to investigate whether and how incretin mimetics, which are commonly used to treat obesity and...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the adhesion G-protein coupled receptor L1 (ADGRL1) in the hypothalamus for counteracting hypoglycemia. The $538,354 award, with a project period from June 17, 2025 to March 31, 2030, will fund research to establish ADGRL1's contribution to the...
The federal Project Grant award of $804,342.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research at Duke University focused on understanding the complex metabolic actions of the hormone glucagon beyond its canonical role in preventing hypoglycemia. The research aims to elucidate how glucagon receptor signaling in hepatocytes engages divergent pathways...
This $2,782,476 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) supports research at Florida State University to investigate the molecular mechanisms underlying beta cell response to metabolic stress in type 2 diabetes (T2D). The goal is to determine how the transition from adaptive to maladaptive beta cell responses to overnutrition (high glucose and lipids) is mediated by epigenetic programs. The research involves comprehensive...

ALPHA- TO BETA-CELL COMMUNICATION IN HEALTH AND DISEASE - SUMMARY OF WORK GLUCAGON IS CANONICALLY VIEWED AS AN ESSENTIAL COUNTERREGULATORY HORMONE THAT PREVENTS HYPOGLYCEMIA BY DRIVING ENDOGENOUS GLUCOSE PRODUCTION (EGP) IN THE LIVER. WE AND OTHERS HAVE REVEALED ADDITIONAL ROLES FOR GLUCAGON THAT EMPHASIZE A MUCH MORE COMPLEX CONTROL OF METABOLISM BEYOND HYPOGLYCEMIA. ON SUCH ROLE IS OUR STUDIES REVEALING THE POTENT INSULINOTROPIC ACTIONS OF GLUCAGON IN B-CELLS, WHICH WE HAVE SHOWN TO BE ESSENTIAL FOR POSTPRANDIAL GLUCOSE CONTROL. GLUCAGON PRODUCTION IN A-CELLS COMES FROM THE SPECIFIC PROCESSING OF A PROGLUCAGON PEPTIDE BY PROHORMONE CONVERTASE 2 (PC2). EMERGING LITERATURE HAS PROPOSED THAT A-CELLS CAN DIFFERENTIALLY PROCESS THE PROGLUCAGON HORMONE TO PRODUCE GLUCAGON-LIKE PEPTIDE 1 (GLP-1) THROUGH A DISTINCT PROHOROMONE CONVERTASE; PC1. GLP-1 IS A MUCH MORE POTENT INSULINOTROPIC PEPTIDE, WHICH WOULD ENHANCE A- TO B-CELL COMMUNICATION AND INSULIN SECRETION TO A GREATER EXTENT THAN GLUCAGON. OUR WORK IN HUMAN SUBJECTS HAS SUGGESTED THAT A- TO B-CELL COMMUNICATION BECOMES GREATER CONTRIBUTOR TO INSULIN SECRETION WITH INCREASE METABOLIC STRESS, RAISING THE HYPOTHESIS THAT MECHANISMS THAT ENHANCE THIS AXIS MAY DO SO A COMPENSATORY MECHANISM TO ENHANCE INSULIN SECRETION IN THE SETTING OF INCREASE PERIPHERAL INSULIN RESISTANCE THAT ASSOCIATES WITH OBESITY AND/OR TYPE 2 DIABETES (T2D). WE HAVE GENERATED SEVERAL MOUSE MODELS THAT SUPPORT THIS HYPOTHESIS WITH STRONG PRELIMINARY DATA AND PROPOSE HERE TO MOVE THIS HYPOTHESIS INTO A TRANSLATIONAL SETTING. WE WILL UTILIZE PRECLINICAL STUDIES IN HUMAN ISLETS AS WELL AS CLINICAL STUDIES IN HUMAN SUBJECTS TO TEST THE IMPORTANCE OF A- TO B- CELL COMMUNICATION FOR INSULIN SECRETION ACROSS THE METABOLIC SPECTRUM AND ENHANCE OUR UNDERSTANDING OF HOW A-CELLS PROCESS PROGLUCAGON PEPTIDES TO SUPPORT B-CELL FUNCTION. THIS WORK HAS DIRECT IMPLICATIONS IN THE UNDERSTANDING OF THE PATHOGENESIS OF T2D AS WELL AS THE MECHANISMS BY WHICH INCRETIN-BASED DRUGS CONTROL GLUCOSE HOMEOSTASIS.

Posted 9/19/24